{"id":66678,"date":"2026-05-29T13:24:56","date_gmt":"2026-05-29T05:24:56","guid":{"rendered":"https:\/\/flcube.com\/?p=66678"},"modified":"2026-05-29T13:24:57","modified_gmt":"2026-05-29T05:24:57","slug":"suzhou-ribo-life-science-files-phase-ii-ema-application-for-rbd1119-novel-sirna-antithrombotic-for-coronary-artery-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66678","title":{"rendered":"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Suzhou Ribo Life Science Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6938:HKG\">HKG: 6938<\/a>) announced it has submitted a <strong>Phase II clinical trial application<\/strong> to the <strong>European Medicines Agency (EMA)<\/strong> for <strong>RBD1119<\/strong>, a <strong>small interfering RNA (siRNA) drug<\/strong> developed for the treatment of <strong>coronary artery disease (CAD)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-filing-details\" class=\"wp-block-heading\">Regulatory Filing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>EMA (European Union)<\/td><\/tr><tr><td><strong>Filing Type<\/strong><\/td><td>Phase II Clinical Trial Application<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>RBD1119 (siRNA therapeutic)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of coronary artery disease<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>29 May 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>EMA review period; potential approval for Phase II initiation within 60-90 days<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Small interfering RNA (siRNA) antithrombotic therapeutic<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Developed using Ribo Life Sciences&#8217; proprietary <strong>RiboGalSTAR siRNA platform<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> Thrombosis-related factors involved in CAD progression<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Provides <strong>effective and durable thromboprophylaxis<\/strong> while maintaining a <strong>favorable safety profile<\/strong>, particularly regarding bleeding risk<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Addresses limitations of current antiplatelet and anticoagulant therapies that inadequately control thrombotic events<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-amp-market-context\" class=\"wp-block-heading\">Clinical &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Current Standard of Care<\/th><th>RBD1119 Potential Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Therapeutic Approach<\/strong><\/td><td>Antiplatelet\/anticoagulant drugs<\/td><td>Targeted siRNA therapy<\/td><\/tr><tr><td><strong>Efficacy<\/strong><\/td><td>Inadequate control of thrombotic events<\/td><td>Potentially superior thromboprophylaxis<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Significant bleeding risk<\/td><td>Favorable safety profile with reduced bleeding risk<\/td><\/tr><tr><td><strong>Durability<\/strong><\/td><td>Requires continuous dosing<\/td><td>Potential for extended effect due to siRNA mechanism<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Coronary artery disease remains a leading cause of morbidity and mortality among cardiovascular patients worldwide, creating substantial unmet medical need.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>European CAD Market:<\/strong> Estimated at \u20ac8.2 billion annually, with limited innovation in antithrombotic therapies over the past decade<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> RBD1119 would be among the first siRNA-based antithrombotics to reach European markets if approved<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> EMA filing represents a key milestone in Ribo Life Science&#8217;s international expansion beyond its Chinese base<\/li>\n\n\n\n<li><strong>Investment Implications:<\/strong> Successful Phase II results could significantly enhance the company&#8217;s valuation and attract partnership interest from major cardiovascular-focused pharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory filings, clinical development, and commercial potential for RBD1119. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[4524,1725],"class_list":["post-66678","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-hkg-6938","tag-ribo-life-science"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II clinical trial application to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug developed for the treatment of coronary artery disease (CAD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66678\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease\" \/>\n<meta property=\"og:description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II clinical trial application to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug developed for the treatment of coronary artery disease (CAD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66678\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T05:24:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T05:24:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66678#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66678\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease\",\"datePublished\":\"2026-05-29T05:24:56+00:00\",\"dateModified\":\"2026-05-29T05:24:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66678\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 6938\",\"Ribo Life Science\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66678#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66678\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66678\",\"name\":\"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T05:24:56+00:00\",\"dateModified\":\"2026-05-29T05:24:57+00:00\",\"description\":\"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II clinical trial application to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug developed for the treatment of coronary artery disease (CAD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66678#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66678\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66678#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II clinical trial application to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug developed for the treatment of coronary artery disease (CAD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66678","og_locale":"en_US","og_type":"article","og_title":"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease","og_description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II clinical trial application to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug developed for the treatment of coronary artery disease (CAD).","og_url":"https:\/\/flcube.com\/?p=66678","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T05:24:56+00:00","article_modified_time":"2026-05-29T05:24:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66678#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66678"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease","datePublished":"2026-05-29T05:24:56+00:00","dateModified":"2026-05-29T05:24:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66678"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 6938","Ribo Life Science"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66678#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66678","url":"https:\/\/flcube.com\/?p=66678","name":"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T05:24:56+00:00","dateModified":"2026-05-29T05:24:57+00:00","description":"Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II clinical trial application to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug developed for the treatment of coronary artery disease (CAD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66678#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66678"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66678#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 \u2013 Novel siRNA Antithrombotic for Coronary Artery Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66678"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66678\/revisions"}],"predecessor-version":[{"id":66679,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66678\/revisions\/66679"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}